[HTML][HTML] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - Elsevier
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to
severe plaque psoriasis. Methods This phase III, multicenter, double-blind, placebo-
controlled study randomized adults (2: 1) to apremilast or placebo. At week 16, the placebo
group switched to apremilast through week 32, followed by a randomized treatment
withdrawal phase to week 52. Binary end points were analyzed using χ 2 test; continuous …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to
severe plaque psoriasis. Methods This phase III, multicenter, double-blind, placebo-
controlled study randomized adults (2: 1) to apremilast or placebo. At week 16, the placebo
group switched to apremilast through week 32, followed by a randomized treatment
withdrawal phase to week 52. Binary end points were analyzed using χ 2 test; continuous …